IL1B and Parkinson disease: Studies on animal models suggest that butyrate may potentially mitigate neurological damage in PD by inhibiting the over-activation of nigrostriatal microglia and suppressing the expression of inflammatory factors like TNF-α, IL-6, and IL-1β (Hou et al., 2021).